Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Bcl6 and Blimp1 reciprocally regulate ST2+ Treg cell development in the context of allergic airway inflammation.

Koh B, Ulrich BJ, Nelson AS, Panangipalli G, Kharwadkar R, Wu W, Xie MM, Fu Y, Turner MJ, Paczesny S, Chandra Janga S, Dent AL, Kaplan MH.

J Allergy Clin Immunol. 2020 Mar 13. pii: S0091-6749(20)30340-7. doi: 10.1016/j.jaci.2020.03.002. [Epub ahead of print]

PMID:
32179158
2.

Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.

Paczesny S.

Br J Haematol. 2020 Feb 10. doi: 10.1111/bjh.16497. [Epub ahead of print]

PMID:
32039480
3.

Assessment of ST2 for risk of death following graft-versus-host disease in the pediatric and adult age groups.

Rowan C, Pike F, Cooke KR, Krance R, Carpenter PA, Duncan C, Jacobsohn DA, Bollard CM, Cruz CRY, Malatpure A, Farag SS, Renbarger J, Liu H, Bakoyannis G, Hanash S, Paczesny S.

Blood. 2020 Jan 23. pii: blood.2019002334. doi: 10.1182/blood.2019002334. [Epub ahead of print]

PMID:
31972009
4.

GVHD risk assessment beyond current HLA evaluation.

Paczesny S.

Lancet Haematol. 2020 Jan;7(1):e8-e9. doi: 10.1016/S2352-3026(19)30221-2. Epub 2019 Oct 25. No abstract available.

PMID:
31669247
5.

Ex vivo culture of mouse skin activates an interleukin 1 alpha-dependent inflammatory response.

Zhou HM, Slominski RM, Seymour LJ, Bell MC, Dave P, Atumonye J, Wright W 3rd, Dawes A, Griesenauer B, Paczesny S, Kaplan MH, Spandau DF, Turner MJ.

Exp Dermatol. 2020 Jan;29(1):102-106. doi: 10.1111/exd.14044. Epub 2019 Oct 16.

PMID:
31566815
6.

Early high plasma ST2, the decoy IL-33 receptor, in children undergoing hematopoietic cell transplantation is associated with the development of post-transplant diabetes mellitus.

Rowan CM, Teagarden AM, Cater DT, Moser EAS, Bakoyannis G, Paczesny S.

Haematologica. 2019 Aug 29. pii: haematol.2019.222992. doi: 10.3324/haematol.2019.222992. [Epub ahead of print]

7.

Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths.

Karaesmen E, Hahn T, Dile AJ, Rizvi AA, Wang J, Wang T, Haagenson MD, Preus L, Zhu Q, Liu Q, Yan L, Liu S, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, McCarthy PL, Pasquini MC, Spellman SR, Lee SJ, Paczesny S, Sucheston-Campbell LE.

Blood Adv. 2019 Aug 27;3(16):2512-2524. doi: 10.1182/bloodadvances.2019000075.

8.

Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute Leukemia.

Tsamadou C, Fürst D, Wang T, He N, Lee SJ, Spellman SR, Fleischhauer K, Hsu KC, Paczesny S, Verneris MR, Schrezenmeier H, Mytilineos J.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2357-2365. doi: 10.1016/j.bbmt.2019.08.007. Epub 2019 Aug 16.

9.

Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology.

Liu X, Yue Z, Cao Y, Taylor L, Zhang Q, Choi SW, Hanash S, Ito S, Chen JY, Wu H, Paczesny S.

JCO Precis Oncol. 2019;3. doi: 10.1200/po.18.00365. Epub 2019 May 23.

10.

Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT.

Tang H, Hahn T, Karaesmen E, Rizvi AA, Wang J, Paczesny S, Wang T, Preus L, Zhu Q, Wang Y, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, Pasquini MC, McCarthy PL, Spellman SR, Sucheston-Campbell LE.

Blood Adv. 2019 Aug 13;3(15):2337-2341. doi: 10.1182/bloodadvances.2019000052. No abstract available.

11.

ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.

Griesenauer B, Jiang H, Yang J, Zhang J, Ramadan AM, Egbosiuba J, Campa K, Paczesny S.

J Immunol. 2019 May 15;202(10):3053-3064. doi: 10.4049/jimmunol.1800447. Epub 2019 Apr 12.

PMID:
30979817
12.

Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.

Rowan CM, Paczesny S.

Clin Lab Med. 2019 Mar;39(1):61-72. doi: 10.1016/j.cll.2018.10.005. Epub 2018 Dec 18. Review.

PMID:
30709509
13.

Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.

Yang J, Ramadan A, Reichenbach DK, Loschi M, Zhang J, Griesenauer B, Liu H, Hippen KL, Blazar BR, Paczesny S.

JCI Insight. 2019 Mar 7;4(5). pii: 122014. doi: 10.1172/jci.insight.122014. eCollection 2019 Mar 7.

14.

Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.

Paczesny S, Metzger J.

Proteomics Clin Appl. 2019 Mar;13(2):e1800145. doi: 10.1002/prca.201800145. Epub 2018 Oct 17. Review.

15.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.

Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C; GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee.

Haematologica. 2018 Oct;103(10):1708-1719. doi: 10.3324/haematol.2017.182550. Epub 2018 Aug 3.

16.

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Ramadan AM, Daguindau E, Rech JC, Chinnaswamy K, Zhang J, Hura GL, Griesenauer B, Bolten Z, Robida A, Larsen M, Stuckey JA, Yang CY, Paczesny S.

JCI Insight. 2018 Jul 26;3(14). pii: 99208. doi: 10.1172/jci.insight.99208. eCollection 2018 Jul 26.

17.

Less cholesterol means better tumor killing for cytotoxic T9 cells.

Griesenauer B, Paczesny S.

J Exp Med. 2018 Jun 4;215(6):1505-1506. doi: 10.1084/jem.20180852. Epub 2018 May 15.

18.

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Paczesny S, Pavletic SZ, Bollard CM.

Blood. 2018 Jun 14;131(24):2617-2620. doi: 10.1182/blood-2018-04-840793. Epub 2018 May 4.

19.

The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Ren HG, Adom D, Paczesny S.

Expert Rev Clin Immunol. 2018 May;14(5):389-404. doi: 10.1080/1744666X.2018.1463159. Epub 2018 Apr 19. Review.

20.

Biomarkers for posttransplantation outcomes.

Paczesny S.

Blood. 2018 May 17;131(20):2193-2204. doi: 10.1182/blood-2018-02-791509. Epub 2018 Apr 5. Review.

21.

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Palam LR, Mali RS, Ramdas B, Srivatsan SN, Visconte V, Tiu RV, Vanhaesebroeck B, Roers A, Gerbaulet A, Xu M, Janga SC, Takemoto CM, Paczesny S, Kapur R.

JCI Insight. 2018 Feb 22;3(4). pii: 94679. doi: 10.1172/jci.insight.94679. eCollection 2018 Feb 22.

22.

Biomarkers in chronic graft-versus-host disease: quo vadis?

Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, Hakim F, Malard F, Jagasia M, Lawitschka A, Hansen JA, Pulanic D, Holler E, Dickinson A, Weissinger E, Edinger M, Sarantopoulos S, Schultz KR.

Bone Marrow Transplant. 2018 Jul;53(7):832-837. doi: 10.1038/s41409-018-0092-x. Epub 2018 Jan 24.

23.

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

Du J, Flynn R, Paz K, Ren HG, Ogata Y, Zhang Q, Gafken PR, Storer BE, Roy NH, Burkhardt JK, Mathews W, Tolar J, Lee SJ, Blazar BR, Paczesny S.

Blood. 2018 Apr 12;131(15):1743-1754. doi: 10.1182/blood-2017-08-800623. Epub 2018 Jan 18.

24.

Neonatal hyperoxia promotes asthma-like features through IL-33-dependent ILC2 responses.

Cheon IS, Son YM, Jiang L, Goplen NP, Kaplan MH, Limper AH, Kita H, Paczesny S, Prakash YS, Tepper R, Ahlfeld SK, Sun J.

J Allergy Clin Immunol. 2018 Oct;142(4):1100-1112. doi: 10.1016/j.jaci.2017.11.025. Epub 2017 Dec 15.

25.

Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.

Seo S, Yu J, Jenkins IC, Leisenring WM, Steven-Ayers T, Kuypers JM, Huang ML, Jerome KR, Boeckh M, Paczesny S.

Biol Blood Marrow Transplant. 2018 Apr;24(4):678-686. doi: 10.1016/j.bbmt.2017.11.039. Epub 2017 Dec 6.

26.

Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.

Ramadan A, Griesenauer B, Adom D, Kapur R, Hanenberg H, Liu C, Kaplan MH, Paczesny S.

J Exp Med. 2017 Dec 4;214(12):3577-3596. doi: 10.1084/jem.20170041. Epub 2017 Oct 16.

27.

Editorial: Danger Signals Triggering Immune Response and Inflammation.

Ramadan A, Land WG, Paczesny S.

Front Immunol. 2017 Aug 11;8:979. doi: 10.3389/fimmu.2017.00979. eCollection 2017. No abstract available.

28.

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.

Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1660. doi: 10.3390/ijms18081660. Review.

29.

Acute Graft-Versus-Host Disease Prognosis: Are Biomarkers Ready for Preemptive Clinical Trials?

Paczesny S.

Clin Chem. 2017 Oct;63(10):1561-1563. doi: 10.1373/clinchem.2017.272872. Epub 2017 Jul 7. No abstract available.

PMID:
28687636
30.

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR.

JCI Insight. 2017 Jun 15;2(12). pii: 92111. doi: 10.1172/jci.insight.92111. eCollection 2017 Jun 15.

31.

The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.

Griesenauer B, Paczesny S.

Front Immunol. 2017 Apr 24;8:475. doi: 10.3389/fimmu.2017.00475. eCollection 2017. Review.

32.

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.

Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR.

Bone Marrow Transplant. 2017 Jul;52(7):1010-1015. doi: 10.1038/bmt.2017.73. Epub 2017 May 8.

33.

Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.

Inamoto Y, Martin PJ, Paczesny S, Tabellini L, Momin AA, Mumaw CL, Flowers MED, Lee SJ, Carpenter PA, Storer BE, Hanash S, Hansen JA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1250-1256. doi: 10.1016/j.bbmt.2017.04.019. Epub 2017 Apr 25.

34.

Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.

Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, Daguindau E, Olmsted T, Mumaw C, Towlerton AMH, Cooke KR, O'Donnell PV, Symons HJ, Paczesny S, Luznik L.

Haematologica. 2017 May;102(5):932-940. doi: 10.3324/haematol.2016.152322. Epub 2017 Jan 25.

35.

Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

Johnpulle RA, Paczesny S, Jung DK, Daguindau E, Jagasia MH, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Byrne MT, Engelhardt BG.

Biol Blood Marrow Transplant. 2017 Mar;23(3):529-532. doi: 10.1016/j.bbmt.2016.12.627. Epub 2016 Dec 21.

36.

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW.

Blood. 2017 Jan 12;129(2):162-170. doi: 10.1182/blood-2016-08-735324. Epub 2016 Nov 8.

37.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR.

Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14. Review.

38.

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR.

Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3. Review.

39.

JAK polymorphisms: jack of all cytokines, masters GVHD?

Kushekhar K, Paczesny S.

Leuk Lymphoma. 2017 Feb;58(2):255-256. Epub 2016 Aug 9. No abstract available.

PMID:
27685636
40.

Improved reproducibility and quality of GvHD biomarker assay: application of multiplex microfluidic channel system.

Anandi P, Tian X, Chinian F, Cantilena CR, Dunavin N, Hensel N, Draper D, Koklanaris E, Maxwell S, Superata J, Muranski P, Battiwalla M, Paczesny S, Barrett AJ, Ito S.

Bone Marrow Transplant. 2016 Dec;51(12):1615-1616. doi: 10.1038/bmt.2016.226. Epub 2016 Sep 5. No abstract available.

PMID:
27595279
41.

CXCL10: most consistent cGVHD biomarker?

Paczesny S, Abu Zaid M.

Blood. 2016 Jun 16;127(24):2950-1. doi: 10.1182/blood-2016-04-709543. No abstract available.

42.

Biomarker Panel for Chronic Graft-Versus-Host Disease.

Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y, Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, Pidala J, Hamilton BK, Chen GL, Pusic I, Lee SJ, Paczesny S.

J Clin Oncol. 2016 Aug 1;34(22):2583-90. doi: 10.1200/JCO.2015.65.9615. Epub 2016 May 23.

43.

Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

Li W, Liu L, Gomez A, Zhang J, Ramadan A, Zhang Q, Choi SW, Zhang P, Greenson JK, Liu C, Jiang D, Virts E, Kelich SL, Chu HW, Flynn R, Blazar BR, Hanenberg H, Hanash S, Paczesny S.

JCI Insight. 2016 May 5;1(6). pii: 86660. doi: 10.1172/jci.insight.86660.

44.

Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.

Liu X, Yue Z, Yu J, Daguindau E, Kushekhar K, Zhang Q, Ogata Y, Gafken PR, Inamoto Y, Gracon A, Wilkes DS, Hansen JA, Lee SJ, Chen JY, Paczesny S.

Am J Transplant. 2016 Aug;16(8):2342-51. doi: 10.1111/ajt.13750. Epub 2016 Mar 14.

45.

Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation.

Engelhardt BG, Paczesny S, Jung DK, Daguindau E, Jagasia M, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Yoder SM, Rock MT, Crowe JE Jr.

Haematologica. 2016 May;101(5):e204-8. doi: 10.3324/haematol.2015.139501. Epub 2016 Jan 27. No abstract available.

46.

SNPs and prognosis of GvHD before HCT: any progress?

Abu Zaid MI, Paczesny S, Miklos DB.

Bone Marrow Transplant. 2016 Feb;51(2):161-2. doi: 10.1038/bmt.2015.240. Epub 2015 Oct 12. No abstract available.

PMID:
26457906
47.

ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.

Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, Kapur R, Hanenberg H, Blazar BR, Tawara I, Paczesny S.

Sci Transl Med. 2015 Oct 7;7(308):308ra160. doi: 10.1126/scitranslmed.aab0166.

48.

Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.

Akil A, Zhang Q, Mumaw CL, Raiker N, Yu J, Velez de Mendizabal N, Haneline LS, Robertson KA, Skiles J, Diaz-Ricart M, Carreras E, Renbarger J, Hanash S, Bies RR, Paczesny S.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1739-45. doi: 10.1016/j.bbmt.2015.07.004. Epub 2015 Jul 11.

49.

Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.

Ramadan A, Paczesny S.

Front Immunol. 2015 Jan 28;6:14. doi: 10.3389/fimmu.2015.00014. eCollection 2015. Review.

50.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, Hansen J, Jagasia M, Miklos D, Pavletic S, Parkman R, Russek-Cohen E, Flowers ME, Lee S, Martin P, Vogelsang G, Walton M, Schultz KR.

Biol Blood Marrow Transplant. 2015 May;21(5):780-92. doi: 10.1016/j.bbmt.2015.01.003. Epub 2015 Jan 30.

Supplemental Content

Loading ...
Support Center